ライフサイエンスコーパス: acetylcholinesterase

1 etylcholinesterase) or nonexisting (synaptic acetylcholinesterase).

2 sly validated for imaging cerebral levels of acetylcholinesterase.

3 f cholinergic transmission via inhibition of acetylcholinesterase.

4 resulted in a comparable enhanced release of acetylcholinesterase.

5 he essential oil was the most active against acetylcholinesterase.

6 , octopamine synapses, and the inhibition of acetylcholinesterase.

7 components of decay, even in the presence of acetylcholinesterase.

8 re homologous to the dimerization helices of acetylcholinesterase.

9 s they react preferentially to inhibit human acetylcholinesterase.

10 s, in addition to inhibiting the activity of acetylcholinesterase.

11 ors, it leads to resistance to inhibitors of acetylcholinesterase.

12 decreased polyploidization and staining for acetylcholinesterase.

13 Acetylcholinesterase 1 (AmAChE1) of the honey bee, Apis

14 ic effects by inhibiting the action of human acetylcholinesterase, a member of the serine hydrolase s

15 potential label-free detection system, using acetylcholinesterase (acetylcholine acetylhydrolase; EC

16 neonatal optic nerve transection on cortical acetylcholinesterase (AChE) activity in hooded rats duri

17 NeuN (for neuronal counts), or processed for acetylcholinesterase (AChE) activity or p75 immunoreacti

18 or their potential inhibitory effect on both acetylcholinesterase (AChE) and butyrylcholinesterase (B

19 en advantage of the distinct localization of acetylcholinesterase (AChE) and butyrylcholinesterase (B

20 tinus L. was investigated via inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (B

21 erases involved in neural processes, such as acetylcholinesterase (AChE) and butyrylcholinesterase (B

22 s acid (HOCl) assays, and their potential as acetylcholinesterase (AChE) and butyrylcholinesterase (B

23 The cholinesterases, acetylcholinesterase (AChE) and butyrylcholinesterase, a

24 based on poly(o-phenylenediamine) (PoPD) and acetylcholinesterase (AChE) and choline oxidase (ChO) en

25 by co-immobilizing covalently, a mixture of acetylcholinesterase (AChE) and choline oxidase (ChO) on

26 tion is constructed by immobilizing enzymes, acetylcholinesterase (AChE) and choline oxidase (ChO), o

27 wed by chemical cross-linking of the enzymes acetylcholinesterase (AChE) and choline oxidase (ChO).

28 We show that miR-608 targets acetylcholinesterase (AChE) and demonstrate weakened miR

29 ouble stranded RNA (dsRNA) homologous to the acetylcholinesterase (AChE) and ecdysone receptor (EcR)

30 sites of bovine carbonic anhydrase (BCA) or acetylcholinesterase (AChE) and inhibit their catalytic

31 atform for simple and sensitive detection of acetylcholinesterase (AChE) and its inhibitor using a ca

32 targets for Alzheimer's disease (AD), i.e., acetylcholinesterase (AChE) and monoamine oxidase B (MAO

33 The chemistry described here uses acetylcholinesterase (AChE) and produces an unambiguous

34 urvival, as well as aberrant distribution of acetylcholinesterase (AChE) and rapsyn.

35 this work we investigated the expression of acetylcholinesterase (AChE) and the density of myelinate

36 he molecular interactions between the enzyme acetylcholinesterase (AChE) and two compound classes con

37 The catalytic subunits of acetylcholinesterase (AChE) are anchored in the basal la

38 Choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) are the decisive enzymatic a

39 Recently, researchers have used acetylcholinesterase (AChE) as a reaction vessel to synt

40 isplays the identical binding mechanism with acetylcholinesterase (AChE) as its more potent counterpa

41 pectrometric detection and a high throughput acetylcholinesterase (AChE) assay was developed.

42 and effect-directed analysis (EDA) using the acetylcholinesterase (AChE) bioassay and metabolomics.

43 Acetylcholinesterase (AChE) biosensor was developed thro

44 A sensitive electrochemical acetylcholinesterase (AChE) biosensor was successfully d

45 The reactivation of nerve agent-inhibited acetylcholinesterase (AChE) by oxime is the most importa

46 Ligand binding sites on acetylcholinesterase (AChE) comprise an active center, a

47 Acetylcholinesterase (AChE) contains a narrow and deep a

48 Acetylcholinesterase (AChE) converts ACh to choline, whi

49 Towards this, a highly sensitive acetylcholinesterase (AChE) cyclic voltammetric biosenso

50 de organophosphate insecticides that inhibit acetylcholinesterase (AChE) enzyme activity in the salmo

51 e (PHA), which mimics the performance of the acetylcholinesterase (AChE) enzyme.

52 biosensor that employs genetically modified acetylcholinesterase (AChE) enzymes B394, B4 and wild ty

53 Like its homologs in the acetylcholinesterase (AChE) family, ChEL possesses two c

54 Mammalian acetylcholinesterase (AChE) gene expression is exquisite

55 A series of inhibitors of acetylcholinesterase (AChE) have been screened by back-s

56 olive oil, based on a genetically-engineered acetylcholinesterase (AChE) immobilized in a azide-unit

57 aking advantage of the crystal structures of acetylcholinesterase (AChE) in complex with galantamine

58 showed improved inhibitory properties toward acetylcholinesterase (AChE) in relation to tacrine.

59 The synaptic form of acetylcholinesterase (AChE) in skeletal muscle ColQ-AChE

60 The expression of acetylcholinesterase (AChE) in skeletal muscle is regula

61 xicants is due to irreversible inhibition of acetylcholinesterase (AChE) in the nervous system.

62 reased during the initial period and that of acetylcholinesterase (AChE) increased during a later tim

63 ldoximes are used as antidotes to reactivate acetylcholinesterase (AChE) inhibited by organophosphoru

64 valuated using a previously established AOP, acetylcholinesterase (AChE) inhibition.

65 herein that RS67333 is also a submicromolar acetylcholinesterase (AChE) inhibitor and therefore, cou

66 , that bis(heptyl)-cognitin, a novel dimeric acetylcholinesterase (AChE) inhibitor derived from tacri

67 Acetylcholinesterase (AChE) inhibitors are commonly used

68 Acetylcholinesterase (AChE) inhibitors are potentially l

69 ganophosphorus (OP) and methylcarbamate (MC) acetylcholinesterase (AChE) inhibitors.

70 ich sources of phenolic compounds, exhibited acetylcholinesterase (AChE) inhibitory activity and also

71 In vitro, 15 compounds displayed excellent acetylcholinesterase (AChE) inhibitory potencies and int

72 The ACh hydrolyzing enzyme acetylcholinesterase (AChE) is a combinatorial series of

73 Human acetylcholinesterase (AChE) is a significant target for

74 Acetylcholinesterase (AChE) is an enzyme that terminates

75 At cholinergic synapses, acetylcholinesterase (AChE) is critical for ensuring nor

76 Acetylcholinesterase (AChE) is crucial for degrading ace

77 Acetylcholinesterase (AChE) is highly expressed at sites

78 In the central nervous system, acetylcholinesterase (AChE) is present in a tetrameric f

79 By utilizing the acetylcholinesterase (AChE) mediated hydrolysis of acety

80 The vast majority of newly synthesized acetylcholinesterase (AChE) molecules do not assemble in

81 Cytochrome oxidase (CYO) and acetylcholinesterase (AChE) staining density varies acro

82 sensing strategy involves reacting ACh with acetylcholinesterase (AChE) to form choline that is in t

83 frozen, serially sectioned, and stained for acetylcholinesterase (AChE) to identify the NMJs.

84 rseradish peroxidase and surface coated with acetylcholinesterase (AChE) were attached to gold screen

85 -oxime reactivation rates for OP-inactivated acetylcholinesterase (AChE) were lower compared to 2-PAM

86 can be induced in humans through blockade of acetylcholinesterase (AChE) whereas antidepressant-like

87 to investigate inhibition of human BChE and acetylcholinesterase (AChE) with metaproterenol, isoprot

88 tivators of chemical warfare agent inhibited acetylcholinesterase (AChE) with promising in vitro pote

89 ing bovine serum albumin and conjugated with acetylcholinesterase (AChE), an enzyme specific for acet

90 g the N-methyl-d-aspartate receptor (NMDAR), acetylcholinesterase (AChE), and monoamine oxidase B (MA

91 his work, the selected target was the enzyme acetylcholinesterase (AChE), and the AChE-ICERs produced

92 It is selectively reduced by the addition of acetylcholinesterase (AChE), and thus appears to involve

93 ucleus, distinct in cytochrome oxidase (CO), acetylcholinesterase (AChE), and vesicular glutamate tra

94 Inhibitory activity of the conjugates toward acetylcholinesterase (AChE), butyrylcholinesterase (BChE

95 ontain several cholinergic factors including acetylcholinesterase (AChE), choline acetyltransferase (

96 FAS2) and its high-affinity binding protein, acetylcholinesterase (AChE), followed by rapid conformat

97 immunocytochemical stains were performed for acetylcholinesterase (AChE), nicotinamide adenine dinucl

98 results from the irreversible inhibition of acetylcholinesterase (AChE), the enzyme that inactivates

99 oxidation in thioredoxin reductase (TR) and acetylcholinesterase (AchE), whereas cofactor nicotinami

100 whether APP is involved in the regulation of acetylcholinesterase (AChE), which is a key protein of t

101 variable and insensitive to perturbations of acetylcholinesterase (AChE), while slow non-alpha7 recep

102 iated with an abnormal sprouting response of acetylcholinesterase (AChE)-positive fibers, a phenotype

103 fuse tectopulvinar pathway terminated in the acetylcholinesterase (AChE)-rich dorsal pulvinar (Pd), w

104 sly block the active and peripheral sites of acetylcholinesterase (AChE).

105 as the result of irreversible inhibition of acetylcholinesterase (AChE).

106 ity related to an irreversible inhibition of acetylcholinesterase (AChE).

107 tly binding to the active site of the enzyme acetylcholinesterase (AChE).

108 ow antioxidant properties, and inhibit human acetylcholinesterase (AChE).

109 Among its other biological roles, acetylcholinesterase (AChE, EC 3.1.1.7), encoded by two

110 The usually rare read-through variant of acetylcholinesterase (AChE-R) is causally involved in st

111 We reported previously that insect acetylcholinesterases (AChEs) could be selectively and i

112 f synaptic acetylcholine (ACh) by tetrameric acetylcholinesterase (AChEt).

113 ge (thiobarbituric acid reactive substances, acetylcholinesterase, acid phosphatase), no significant

114 lcholine levels resulting from inhibition of acetylcholinesterase act on such receptors.

115 the expression of four muscle marker genes, Acetylcholinesterase, Actin, Troponin I, and Myosin Ligh

116 P = 0.13), but not significant for cortical acetylcholinesterase activity (F = 0.3, P = 0.75).

117 ed a significant regressor effect for limbic acetylcholinesterase activity (F = 10.1, P < 0.0001), bo

118 c (hippocampal and amygdala) and neocortical acetylcholinesterase activity as well as striatal monoam

119 In addition, Smu. 1393c protects acetylcholinesterase activity from being inhibited by tw

120 ation test scores correlated positively with acetylcholinesterase activity in the hippocampal formati

121 O-glycosyl flavonoids on the antioxidant and acetylcholinesterase activity of these juices has been e

122 ecreased the levels of SE-bound CD63/CD9 and acetylcholinesterase activity respectively.

123 nic acetylcholine receptor was increased and acetylcholinesterase activity was reduced versus control

124 cetylcholine type 2 receptor) receptors, and acetylcholinesterase activity were evaluated in RV (n=11

125 ing of the sacral cord reveals expression of acetylcholinesterase activity, ability to synthesize ace

126 using ultra-centrifugation, and analyzed for acetylcholinesterase activity, total proteins, drug conc

127 minimal in the shell in part due to elevated acetylcholinesterase activity.

128 are unique as they completely lack specific acetylcholinesterase activity.

129 lcholine, and paraoxon-induced inhibition of acetylcholinesterase activity.

130 One clue could be that acetylcholinesterase, also present in amyloid plaques, i

131 sting, and [(11)C]methylpiperidyl propionate acetylcholinesterase and [(11)C]dihydrotetrabenazine (DT

132 ased segmentation, and focal misalignment of acetylcholinesterase and AChRs.

133 cally used cholinomimetics that both inhibit acetylcholinesterase and also interact directly with and

134 Acetylcholinesterase and butyrylcholinesterase accumulat

135 ize, we inserted homologous mutations in the acetylcholinesterase and butyrylcholinesterase cDNAs.

136 These hybrids are potent inhibitors of human acetylcholinesterase and butyrylcholinesterase in vitro

137 zed and evaluated for binding potency toward acetylcholinesterase and butyrylcholinesterase using enz

138 biological significance (alpha-glucosidase, acetylcholinesterase and butyrylcholinesterase) and free

139 emon juice and chokeberry controls inhibited acetylcholinesterase and butyrylcholinesterase, and this

140 classification of carbon 11-labeled [11C]PMP acetylcholinesterase and caudate nucleus [11C]DTBZ monoa

141 e hypothesis that time-of-day differences in acetylcholinesterase and choline acetyltransferase expre

142 ta, that is a potent reversible inhibitor of acetylcholinesterase and NMDA receptors, could mitigate

143 rylated state, which allowed comparison with acetylcholinesterase and rationalization of its ability

144 tion of target site resistance genes such as acetylcholinesterase and the GABA receptor.

145 ferase-positive neurons, as well as, reduced acetylcholinesterase and vesicular acetylcholine transpo

146 Sections were simultaneously stained for acetylcholinesterase and with an antibody to the slow my

147 s very similar to the primary target of OPs (acetylcholinesterase) and a unique N-terminal alpha-heli

148 1(R) allele expressing the insensitive G119S acetylcholinesterase, and a resistant allele of an unkno

149 r enzymes: alpha-glucosidase, alpha-amylase, acetylcholinesterase, and butyrylcholinesterase.

150 le, ascorbic acid content, antioxidant, anti-acetylcholinesterase, anti-inflammatory and cytotoxic ac

151 Neuroligin, butyrylcholinesterase, and acetylcholinesterase are members of the alpha,beta-hydro

152 , in butyrylcholinesterase (Arg-386), and in acetylcholinesterase (Arg-395) are conserved in all stud

153 determination of the activity of erythrocyte acetylcholinesterase as a function of substrate concentr

154 nt pathogens, a radical scavenging assay, an acetylcholinesterase assay as well as in situ and ex sit

155 method of fabrication of a highly sensitive acetylcholinesterase biosensor and its application to de

156 A highly sensitive acetylcholinesterase biosensor was developed for detecti

157 ed acetylcholinesterase using the reversible acetylcholinesterase blocker donepezil.

158 ment, [(11)C]methyl-4-piperidinyl propionate acetylcholinesterase brain positron emission tomography

159 t potent inhibitory activities against human acetylcholinesterase, butyrylcholinesterase, and BACE-1,

160 reened for their inhibitory activity against acetylcholinesterase, butyrylcholinesterase, lipoxygenas

161 Moderate inhibition of acetylcholinesterase by extracts of all investigated Ros

162 ilarly to previously described inhibition of acetylcholinesterase by rivastigmine and other carbamate

163 revealed when tissue was stained for SMI32, acetylcholinesterase, calbindin, or calretinin.

164 m sections stained for Nissl bodies, myelin, acetylcholinesterase, calbindin, or cytochrome oxidase,

165 solutions of acetic acid as a route to sense acetylcholinesterase-catalyzed hydrolysis of acetylcholi

166 ion for NADPH diaphorase-expressing, but not acetylcholinesterase-, choline acetyltransferase-, or tr

167 cose oxidase-catalyzed oxidation of glucose, acetylcholinesterase/choline oxidase-mediated hydrolysis

168 d the utility of (11)C-donepezil for imaging acetylcholinesterase densities in peripheral organs, inc

169 (11)C-donepezil PET is suitable for imaging acetylcholinesterase densities in peripheral organs.

170 donepezil was recently validated for imaging acetylcholinesterase density in the brain and peripheral

171 on and acetylcholine receptor clustering and acetylcholinesterase dispersion seen in the Col13a1-/- m

172 , generated against Electrophorus electricus acetylcholinesterase (EeAChE), inhibits EeAChE and BfACh

173 Small quantities of mutated acetylcholinesterase exported from the cell retain activ

174 th time-dependent changes in basal forebrain acetylcholinesterase expression.

175 Currently, the four major nerve targets are acetylcholinesterase for organophosphates and methylcarb

176 The acetylcholinesterase found in the venom of Bungarus fasc

177 The subsequent enhanced release of acetylcholinesterase from the extant cells could reflect

178 athy') but normal acetylcholine receptor and acetylcholinesterase function.

179 ctions but normal acetylcholine receptor and acetylcholinesterase function.

180 We compared biological functions of two acetylcholinesterase genes (TcAce1 and TcAce2) in Tribol

181 lkylamine reactivators of phosphylated human acetylcholinesterase (hAChE) intended to catalyze the hy

182 Human acetylcholinesterase (hAChE), an enzyme mediating synapt

183 sarin, VX, and paraoxon) conjugates of human acetylcholinesterase (hAChE).

184 ine transporter (VAChT) immunoreactivity and acetylcholinesterase histochemistry (AChE).

185 Acetylcholinesterase histology has been used for many ye

186 were evaluated using confocal microscopy and acetylcholinesterase histology.

187 tion volume ratio) and thalamic and cortical acetylcholinesterase hydrolysis rate per minute (k3), re

188 Firstly, an effective acetylcholinesterase immobilized electrode was developed

189 cells was monitored by measuring release of acetylcholinesterase in cell perfusates using the Ellman

190 Feeding flies choline or inhibiting acetylcholinesterase in Pn enhances memory, an effect bl

191 Data from inhibition of acetylcholinesterase, in vivo toxicity tests of a repres

192 lloenzymes that hydrolyze a variety of toxic acetylcholinesterase-inhibiting organophosphorus compoun

193 of dichlorvos based on polydiacethylene and acetylcholinesterase inhibition is developed.

194 teine, two novel reversal drugs that have no acetylcholinesterase inhibition properties.

195 is study investigates, whether pharmacologic acetylcholinesterase inhibition with neostigmine diminis

196 ulating the parasympathetic activity through acetylcholinesterase inhibition, in experimental pulmona

197 s behind this toxidrome in humans, including acetylcholinesterase inhibition, N-methyl-D-aspartate re

198 behavior; they are slightly resistant to the acetylcholinesterase inhibitor aldicarb, and they exhibi

199 naptic morphology and weak resistance to the acetylcholinesterase inhibitor aldicarb, they are signif

200 ctivity had delayed paralysis induced by the acetylcholinesterase inhibitor aldicarb, whereas mutants

201 muscular junction during lethargus using the acetylcholinesterase inhibitor aldicarb.

202 naling mutants and transgenic animals to the acetylcholinesterase inhibitor aldicarb.

203 enhanced sIPSCs after pretreatment with the acetylcholinesterase inhibitor Bw284c51.

204 y of sacral VF neurons in the presence of an acetylcholinesterase inhibitor can be partially ascribed

205 y improved following a 24-week course of the acetylcholinesterase inhibitor donepezil.

206 demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug into brain-penetrabl

207 ments of the neonatal rat spinal cord to the acetylcholinesterase inhibitor edrophonium (EDR).

208 ke freely moving male rats, without using an acetylcholinesterase inhibitor in the perfusion medium.

209 consisting of the epidural injection of the acetylcholinesterase inhibitor neostigmine.

210 The plant-derived acetylcholinesterase inhibitor physostigmine has previou

211 hippocampal (Experiment 2) injections of the acetylcholinesterase inhibitor physostigmine were admini

212 Acetylcholinesterase inhibitor reversal can cause respir

213 eliorating this cholinergic deficit with the acetylcholinesterase inhibitor rivastigmine would reduce

214 Galantamine is an acetylcholinesterase inhibitor that also acts as a posit

215 e the efficacy and safety of galantamine, an acetylcholinesterase inhibitor that also acts as an allo

216 Neostigmine is an acetylcholinesterase inhibitor that ameliorates the effe

217 and functional network enhancements with an acetylcholinesterase inhibitor treatment (donepezil) whe

218 are more likely to cognitively improve with acetylcholinesterase inhibitor treatment.

219 nd no evidence that age, disease severity or acetylcholinesterase inhibitor use influenced rate of de

220 ce for influence by age, disease severity or acetylcholinesterase inhibitor use.

221 and Drug Administration-approved reversible acetylcholinesterase inhibitor used to treat mild to mod

222 observed in 6 of 66 patients who received an acetylcholinesterase inhibitor, 65 of 69 patients who re

223 utants also exhibited hypersensitivity to an acetylcholinesterase inhibitor, aldicarb, uncovering def

224 f C. elegans to the paralyzing affects of an acetylcholinesterase inhibitor, aldicarb.

225 thout an aid, had no previous exposure to an acetylcholinesterase inhibitor, and did not have dementi

226 milar in normal and lesioned animals and the acetylcholinesterase inhibitor, donepezil (1 mg/kg), pro

227 Donepezil, an acetylcholinesterase inhibitor, is an approved drug for

228 ic activation by systemic application of the acetylcholinesterase inhibitor, physostigmine, resulted

229 treatment with donepezil, a centrally active acetylcholinesterase inhibitor, prevented and reversed o

230 macological intervention using donepezil, an acetylcholinesterase inhibitor.

231 With the aim of reducing side effects of acetylcholinesterase inhibitors (AChEIs) during symptoma

232 meta-analysis investigating the influence of acetylcholinesterase inhibitors (AChEIs) therapy on nutr

233 sure of GWV to organophosphate and carbamate acetylcholinesterase inhibitors (AChEis), including pyri

234 These drugs, known as acetylcholinesterase inhibitors (AChEIs), were first app

235 re also limited by common adverse effects of acetylcholinesterase inhibitors and limited availability

236 Acetylcholinesterase inhibitors and memantine hydrochlor

237 s to examine the safety of NMB reversal with acetylcholinesterase inhibitors and muscarinic anticholi

238 se Research Centre who subsequently received acetylcholinesterase inhibitors and underwent magnetic r

239 Acetylcholinesterase inhibitors are commonly used to tre

240 +/- 6.7 years); 71% of the patients were on acetylcholinesterase inhibitors at baseline; mean Mini-M

241 Acetylcholinesterase inhibitors have also been shown to

242 ion tomography predict treatment response to acetylcholinesterase inhibitors in patients with dementi

243 AD, and enhancing cholinergic signaling with acetylcholinesterase inhibitors is currently the primary

244 The response to acetylcholinesterase inhibitors is often disappointing.

245 Treatment with acetylcholinesterase inhibitors resulted in worsened con

246 o acquired myasthenia gravis, treatment with acetylcholinesterase inhibitors should be avoided in DOK

247 e specific examples of the therapeutics from acetylcholinesterase inhibitors to recent anti-Abeta imm

248 Use of acetylcholinesterase inhibitors was prohibited.

249 tor agonists) and organophosphate miticides (acetylcholinesterase inhibitors).

250 The beneficial effects of acetylcholinesterase inhibitors, however, are typically

251 of age, disease severity and baseline use of acetylcholinesterase inhibitors.

252 ves do not have the unwanted side effects of acetylcholinesterase inhibitors.

253 ntration in the neuromuscular junction using acetylcholinesterase inhibitors.

254 Ex vivo determination of the brain acetylcholinesterase inhibitory activity of these compou

255 nds that exert antioxidative, antimicrobial, acetylcholinesterase inhibitory and estrogenic activitie

256 aying both nanomolar dual-binding site (DBS) acetylcholinesterase inhibitory effects and partial 5-HT

257 The hydrolysis of acetylcholine by acetylcholinesterase into choline was monitored in real-

258 Acetylcholinesterase is an enzyme that is intimately ass

259 The overall activity of acetylcholinesterase is found to decline in AD, whereas

260 ncoding the acetylcholine-hydrolyzing enzyme acetylcholinesterase is known to undergo long-lasting tr

261 5-(11)C-methoxy-donepezil, a noncompetitive acetylcholinesterase ligand, was previously validated fo

262 to both the wild-type and H447I mutant mouse acetylcholinesterase (mAChE) have been investigated by u

263 has been validated and applied to the mouse acetylcholinesterase (mAChE) monomer and several tetrame

264 Functionally, iHPs generate acetylcholinesterase(+) megakaryocytes and phagocytic my

265 he graft-host junction were subjected to the acetylcholinesterase method for the demonstration of cor

266 only in the shell, where higher activity of acetylcholinesterase minimizes nAChR desensitization and

267 The response characteristics of acetylcholinesterase-modified AlGaN/GaN solution-gate fi

268 f fluorescent probes-one to detect the total acetylcholinesterase on erythrocytes (RBC-AChE) and the

269 , by directly detecting organophosphorylated acetylcholinesterase (OP-AChE).

270 untermeasures such as antidotes reactivating acetylcholinesterase or scavenging the parent OP.

271 rived butyrylcholinesterase and erythrocytic acetylcholinesterase) or nonexisting (synaptic acetylcho

272 he largest peptidic inhibitors targeting the acetylcholinesterase peripheral site.

273 sferase-positive cells in this region and of acetylcholinesterase-positive fibers throughout the audi

274 2 and (11)C-methylpiperidin-4-yl propionate acetylcholinesterase positron emission tomography and th

275 mouse model overexpressing a miR refractory acetylcholinesterase-R splice variant showed a parallel

276 Acetylcholinesterase rapidly hydrolyzes the neurotransmi

277 thermore, its abundant bungarotoxin-positive acetylcholinesterase receptors are unique as they comple

278 s to assess the bioactivity of a fragment of acetylcholinesterase responsible for its non-enzymatic f

279 This exposure inhibits acetylcholinesterase resulting in increased acetylcholin

280 LQ (collagen-like tail subunit of asymmetric acetylcholinesterase; rs7609897-T: P=1.5 x 10(-10), OR=0

281 To explore a novel acetylcholinesterase species, ascertain the molecular ba

282 Acetylcholinesterase-stained material confirmed that the

283 ious genotypes, myenteric plexus presence by acetylcholinesterase staining and embryonic day 12.5 (E1

284 fAChE forms the canonical dimer found in all acetylcholinesterase structures.

285 osedimented with eHAV but not membrane-bound acetylcholinesterase, suggesting that eHAV, and not vira

286 then evoke a subsequent, enhanced release in acetylcholinesterase that could only be derived from the

287 croinjection of neostigmine, an inhibitor of acetylcholinesterase, that evoked rapid increases in ace

288 known naturally occurring hydrolytic enzyme, acetylcholinesterase, the catalytic activity of which ap

289 Donepezil is a high-affinity ligand for acetylcholinesterase-the enzyme that catabolizes acetylc

290 of beta-amyloid with a peptide derived from acetylcholinesterase: the similarity in action suggests

291 choline which is enzymatically hydrolyzed by acetylcholinesterase to myristic acid and choline to pre

292 antimicrobials, estrogen-like activators and acetylcholinesterase/tyrosinase inhibitors.

293 Some highly efficient enzymes, e.g., acetylcholinesterase, use gating as a tool for controlli

294 e related to the activity of the immobilized acetylcholinesterase using the reversible acetylcholines

295 and naturally unstable "read-through" human acetylcholinesterase variant, AChE-R.

296 re recently, a gene purportedly encoding for acetylcholinesterase was cloned from maize.

297 Acetylcholinesterase was electro-immobilized into a thic

298 We show proof-of-concept where acetylcholinesterase was immobilized on an organosiloxan

299 obiase, catalase, xenobiotic metabolism, and acetylcholinesterase) were measured in the adults.

300 Physostigmine is a well known inhibitor of acetylcholinesterase, which can also activate, potentiat